Research programme: small molecule therapeutics - VistaGen

Drug Profile

Research programme: small molecule therapeutics - VistaGen

Alternative Names: Drug rescue variants - VistaGen

Latest Information Update: 29 Aug 2014

Price : $50

At a glance

  • Originator VistaGen Therapeutics
  • Developer Synterys; VistaGen Therapeutics
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 23 Apr 2014 VistaGen licenses patents entitled Mesoderm and Definitive Endoderm Cell Populations from Icahn School of Medicine
  • 14 Feb 2012 VistaGen has identified its initial top ten drug rescue candidates
  • 09 Dec 2011 Lead candidates from VistaGen's drug rescue research programme may be made available for licensing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top